• Investors may be wondering whether Intuitive Surgical, at around US$482 per share, still offers good value or if most of the opportunity is already priced in.
• The stock has recently moved 2.8% over the last week and 2.6% over the last month, while year to date it is down 14.2% and the 1 year return sits at a 6.3% decline, compared with a 60.1% return over 3 years and 67.2% over 5 years.
• Recent coverage has focused on how Intuitive Surgical fits into longer term themes in medical technology and how investor sentiment can swing between optimism about growth and concern about valuation. This context helps explain why the share price can be positive over multi year periods while still seeing shorter term pullbacks.
• Simply Wall St currently assigns Intuitive Surgical a valuation score of 0 out of 6. This raises fair questions about how traditional methods like P/E, DCF and peer comparisons stack up and whether there is a more complete way to think about value, which will be outlined later in this article.

Intuitive Surgical scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Intuitive Surgical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It effectively asks what those future dollars are worth in current terms.

For Intuitive Surgical, the model used here is a 2 stage Free Cash Flow to Equity approach, based on cash flow projections. The company’s last twelve month free cash flow is about $2.32b. Analyst estimates and extrapolations point to projected free cash flow of $6.14b by 2030, with interim years such as 2026 and 2027 modeled at $4.27b and $4.41b respectively. Estimates beyond the explicit analyst horizon are extrapolated by Simply Wall St.

When all these projected cash flows are discounted back, the model arrives at an estimated intrinsic value of about $370.37 per share. Against a current share price around $482, the DCF output suggests the stock is 30.2% overvalued on this set of assumptions.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Intuitive Surgical may be overvalued by 30.2%. Discover 56 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Intuitive Surgical Price vs Earnings

For profitable companies, the P/E ratio is a useful way to link what you pay per share to the earnings the business is currently generating. It helps you see how many dollars of price you are paying for each dollar of earnings.

What counts as a “normal” P/E depends on how much growth investors expect and how much risk they see. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually call for a lower one.

Intuitive Surgical currently trades on a P/E of 57.33x. That compares with an industry average P/E for Medical Equipment of 25.05x and a peer average of 28.27x, so the stock is priced at a higher multiple than these simple benchmarks.

Simply Wall St’s Fair Ratio for Intuitive Surgical is 35.54x. This is a proprietary estimate of what the P/E could reasonably be, given the company’s earnings growth profile, industry, profit margins, market cap and identified risks. Because it blends these company specific factors, the Fair Ratio can give a more tailored view than broad industry or peer comparisons alone.

Set against the Fair Ratio, the current P/E of 57.33x screens as richer than that implied fair level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Intuitive Surgical Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced as a simple way for you to attach a clear story to your numbers by linking your view on Intuitive Surgical’s future revenue, earnings, margins and fair value to a structured forecast, then comparing that fair value to today’s price to decide whether the stock looks expensive or attractive on your terms.

On Simply Wall St’s Community page, Narratives are available as an easy tool that millions of investors use to set their own assumptions and see an instant fair value output that automatically updates when fresh news, earnings or guidance arrive. This helps your story and valuation stay current without extra work.

Looking at existing Intuitive Surgical Narratives, one investor Narrative on the platform currently anchors on a fair value around US$325.55 per share while another sits closer to US$750.00 per share. This shows how two people can look at the same business, plug in different growth, margin and P/E expectations, and reach very different but clearly explained conclusions that you can then compare with your own view.

For Intuitive Surgical, however, we will make it really easy for you with previews of two leading Intuitive Surgical Narratives:

Fair value: US$532.46 per share

Implied pricing gap versus last close: about 9.4% undervalued using this narrative’s fair value and the recent price around US$482.22

Revenue growth input: 12%

• This narrative focuses on Intuitive Surgical’s role in robotic assisted surgery and the da Vinci ecosystem, including data, training and surgeon tooling.
• It highlights the scale of the installed base and a high share of recurring revenue from instruments, services and software tied to each system.
• The author describes Intuitive as a high quality business with resilient cash generation, while still being careful about how much to pay based on expected long term returns.

Fair value: US$325.55 per share

Implied pricing gap versus last close: about 48.1% overvalued using this narrative’s fair value and the recent price around US$482.22

Revenue growth input: 12%

• This narrative expects Intuitive Surgical to remain a key player in surgical robotics but questions whether the current share price already reflects strong growth and margins.
• It lays out potential growth drivers across new procedures, technology upgrades and global expansion, alongside industry supports such as demand for minimally invasive surgery.
• It also flags risks, including high system costs, regulation, competition, reliance on the da Vinci platform and sensitivity to any slowdown in the growth story.

If you want the full context behind these storylines and the numbers they use, it is worth reading each Narrative in detail and then deciding which set of assumptions feels closest to your own view on Intuitive Surgical.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Intuitive Surgical on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Intuitive Surgical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.